Alexion Pharmaceuticals (Alexion Pharmaceuticals) Market Cap : $40,336 Mil (As of Apr. 26, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alexion Pharmaceuticals's share price for the quarter that ended in Mar. 2021 was $152.91. Alexion Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2021 was 221 Mil. Therefore, Alexion Pharmaceuticals's market cap for the quarter that ended in Mar. 2021 was $33,778 Mil.

Alexion Pharmaceuticals's quarterly market cap increased from Sep. 2020 ($25,060 Mil) to Dec. 2020 ($34,295 Mil) but then declined from Dec. 2020 ($34,295 Mil) to Mar. 2021 ($33,778 Mil).

Alexion Pharmaceuticals's annual market cap increased from Dec. 2018 ($21,760 Mil) to Dec. 2019 ($23,934 Mil) and increased from Dec. 2019 ($23,934 Mil) to Dec. 2020 ($34,295 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alexion Pharmaceuticals's Enterprise Value for Today is $39,584 Mil.

Alexion Pharmaceuticals Market Cap Historical Data

The historical data trend for Alexion Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Market Cap Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Market Cap

Get a 7-Day Free Trial

27,406.40

26,584.86

21,759.96

23,933.60

34,294.68

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Market Cap	Get a 7-Day Free Trial															19,852.57	24,591.78	25,060.17	34,294.68	33,777.82

Competitive Comparison of Alexion Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Alexion Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alexion Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Market Cap falls into.

Alexion Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alexion Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2020 is calculated as

Market Cap (A: Dec. 2020 )	=	Share Price (A: Dec. 2020 )	*	Shares Outstanding (EOP) (A: Dec. 2020 )
	=	$156.24	*	219.5
	=	$34,295

Alexion Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2021 is calculated as

Market Cap (Q: Mar. 2021 )	=	Share Price (Q: Mar. 2021 )	*	Shares Outstanding (EOP) (Q: Mar. 2021 )
	=	$152.91	*	220.9
	=	$33,778

Alexion Pharmaceuticals (NAS:ALXN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Alexion Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974